Protein Tyrosine Phosphatase 1B (PTP1B): Insights into its New Implications in Tumorigenesis

Curr Cancer Drug Targets. 2022;22(3):181-194. doi: 10.2174/1568009622666220128113400.

Abstract

In vivo, tyrosine phosphorylation is a reversible and dynamic process governed by the opposing activities of protein tyrosine kinases and phosphatases. Defective or inappropriate operation of these proteins leads to aberrant tyrosine phosphorylation, which contributes to the development of many human diseases, including cancers. PTP1B, a non-transmembrane phosphatase, is generally considered a negative regulator of the metabolic signaling pathways and a promising drug target for type II diabetes and obesity. Recently, PTP1B is gaining considerable interest due to its important function and therapeutic potential in other diseases. An increasing number of studies have indicated that PTP1B plays a vital role in the initiation and progression of cancers and could be a target for new cancer therapies. Following recent advances in the aspects mentioned above, this review is focused on the major functions of PTP1B in different types of cancer and the underlying mechanisms behind these functions, as well as the potential pharmacological effects of PTP1B inhibitors in cancer therapy.

Keywords: Protein Tyrosine Phosphatase (PTP); Protein Tyrosine Phosphatase 1B (PTP1B); cancer; tumor promoter; tumor suppressor; tyrosine phosphorylation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Transformation, Neoplastic
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Phosphorylation
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1* / metabolism
  • Tyrosine / metabolism

Substances

  • Tyrosine
  • PTPN1 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1